Welcome to Calabar

Calabar develops innovative therapies to treat dry mouth

Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound has undergone a proof-of-concept study showingit to be effective on salivary function. Calabar is actively looking for a partner with excellence in clinical development, marketing and sales to continue the development. For more information contact Business Development.

The company is part of the Karolinska Development AB (publ) portfolio.